A novel selective 11 β -hydroxysteroid dehydrogenase type 1 inhibitor prevents human adipogenesis

I J Bujalska, L L Gathercole, J W Tomlinson, C Darimont¹, J Ermolieff², A N Fanjul², P A Rejto² and P M Stewart

Division of Medical Sciences, The Medical School, Institute of Biomedical Research, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK

¹Nestle Research Center, PO Box 44, Vers-Chez-Les-Blanc, 1000 Lausanne 26, Switzerland

²Pfizer Global Research and Development, La Jolla Laboratories, 10646 Science Center Drive, San Diego, California 92121, USA

(Correspondence should be addressed to P M Stewart; Email: p.m.stewart@bham.ac.uk)

Abstract

Glucocorticoid excess increases fat mass, preferentially within omental depots; yet circulating cortisol concentrations are normal in most patients with metabolic syndrome (MS). At a pre-receptor level, 11 β -hydroxysteroid dehydrogenase type 1 (11 β -HSD1) activates cortisol from cortisone locally within adipose tissue, and inhibition of 11 β -HSD1 in liver and adipose tissue has been proposed as a novel therapy to treat MS by reducing hepatic glucose output and adiposity. Using a transformed human subcutaneous preadipocyte cell line (Chub-S7) and human primary preadipocytes, we have defined the role of glucocorticoids and 11 β -HSD1 in regulating adipose tissue differentiation. Human cells were differentiated with 1.0 μ M cortisol (F), or cortisone (E) with or without 100 nM of a highly selective 11 β -HSD1 inhibitor PF-877423. 11 β -HSD1 mRNA expression increased across adipocyte differentiation ($P < 0.001$, $n = 4$), which was

paralleled by an increase in 11 β -HSD1 oxo-reductase activity (from nil on day 0 to 5.9 ± 1.9 pmol/mg per h on day 16, $P < 0.01$, $n = 7$). Cortisone enhanced adipocyte differentiation; fatty acid-binding protein 4 expression increased 312-fold ($P < 0.001$) and glycerol-3-phosphate dehydrogenase 47-fold ($P < 0.001$) versus controls. This was abolished by co-incubation with PF-877423. In addition, cellular lipid content decreased significantly. These findings were confirmed in the primary cultures of human subcutaneous preadipocytes. The increase in 11 β -HSD1 mRNA expression and activity is essential for the induction of human adipogenesis. Blocking adipogenesis with a novel and specific 11 β -HSD1 inhibitor may represent a novel approach to treat obesity in patients with MS.

Journal of Endocrinology (2008) **197**, 297–307

Introduction

Glucocorticoid excess (Cushing's syndrome) causes visceral obesity, insulin resistance, diabetes mellitus, dyslipidaemia, hypertension and premature vascular mortality; as such it represents an excellent paradigm for patients with the metabolic syndrome (MS). However, Cushing's syndrome is rare and circulating glucocorticoid levels are usually normal or even slightly reduced in obese patients (Fraser *et al.* 1999). At a cellular level, glucocorticoids within human adipose tissue, specifically in omental depots, can be generated from inactive circulating cortisone (in humans) or 11-dehydrocorticosterone (in rodents) through the oxo-reductase activity of 11 β -hydroxysteroid dehydrogenase type 1 (11 β -HSD1; Bujalska *et al.* 1997b). Transgenic mice with adipose tissue-targeted 11 β -HSD1 overexpression develop visceral obesity, insulin resistance, hyperlipidaemia and hypertension without altering circulating glucocorticoids (Masuzaki *et al.* 2001, 2003), while mice with 11 β -HSD1 overexpression in the liver develop MS without obesity (Paterson *et al.* 2004). Conversely, global deletion of

11 β -HSD1 caused reduced visceral fat accumulation and improved insulin sensitivity on a high fat diet (Kotelevtsev *et al.* 1997, Morton *et al.* 2004). At a molecular level, glucocorticoids exert potent effects upon adipose tissue; in mature rat adipocytes, dexamethasone decreases glucose uptake and oxidation (Olefsky 1975, De *et al.* 1981). Glucocorticoids increase lipolysis by up-regulating the expression of the rate-limiting enzyme hormone-sensitive lipase (Slavin *et al.* 1994), as well as lipogenic enzyme, lipoprotein lipase (Yang *et al.* 1993). In preadipocytes, glucocorticoids are essential for terminal adipogenesis (Hauner *et al.* 1987) and limit cell proliferation (Tomlinson *et al.* 2002). The process of cellular differentiation is a highly synchronized cascade of regulated differentiation-dependent gene expression. Genes such as retinoblastoma proteins that regulate the cell cycle (Richon *et al.* 1997) are followed by adipogenic transcription factors, such as peroxisome proliferator-activated receptor γ (PPAR γ) and CCAAT enhancer-binding protein (Rosen & MacDougald 2006). Mature adipocytes express late differentiation genes involved in lipid metabolism and lipid transport including

glycerol-3-phosphate dehydrogenase (G3PD) and fatty acid-binding protein 4 (FABP4; Hotamisligil *et al.* 1996); many of these genes are regulated by glucocorticoids (Wu *et al.* 1996, Rosen & MacDougald 2006). Previously, we have shown that non-selective inhibition of 11 β -HSD1 can prevent human adipocyte differentiation *in vitro* (Bujalska *et al.* 1999). The potential for therapeutic intervention has been tested in rodent models where selective 11 β -HSD1 inhibitors lower plasma glucose, improve insulin sensitivity and in some studies reduce body weight in mice (Alberts *et al.* 2002, Kershaw *et al.* 2005). However, the potency of these inhibitors has been variable and there are no data on efficacy in human tissue. We report the development of a selective inhibitor against human 11 β -HSD1, PF-877423 (Pfizer Global R&D, La Jolla, CA, USA) and the effect of this compound upon adipogenesis in a well-characterised differentiating human subcutaneous preadipocyte cell line (Darimont *et al.* 2003, Qiao *et al.* 2005) and in primary cultures of subcutaneous human preadipocytes.

Research design and methods

Recombinant protein assay

Wild-type recombinant human 11 β -HSD1 protein (24–292) was used for studying the inhibitor kinetics. Radio-labelled [1,2-³H]-cortisone was purchased from American Radio-labeled Chemicals Inc (St Louis, MO, USA). NAD (reduced form; NADPH), glucose-6-phosphate (G6P) and G6P dehydrogenase (G6PD) were purchased from Sigma-Aldrich. All the concentrations reported in the following section are final in the assay buffer. In addition, the enzyme concentrations represent the active concentrations that were determined by active-site titration using a tight-binding inhibitor. The experimental data were fitted by using the non-linear regression analysis software, Grafit (Leatherbarrow (2001) GraFit Version 5, Erithacus Software Ltd, Horley, UK).

The measurement of the *in vitro* 11 β -HSD1 activity was performed in a 100 mM triethanolamine buffer (pH 8.0), containing 200 mM NaCl, 0.02% *n*-dodecyl β -D-maltoside, 5% glycerol and 5 mM β -mercaptoethanol. A typical reaction for the determination of enzyme activity comprised the following: 5 nM enzyme pre-incubated for at least 30 minutes in the assay buffer in the presence of 500 μ M NADPH in round-bottom 96-well plates (Costar cat # 3365). Next, the reaction was initiated by adding a regenerating system (consisting of 2 mM G6P, 1 U/ml G6PD and 6 mM MgCl₂) and labelled ³H-cortisone as substrate. After an incubation period (30–40 min), 100 μ l of the assay mixture were transferred to a second empty round-bottom 96-well plate and mixed with an equal volume of dimethylsulphoxide (DMSO) to quench the reaction. Then, a 15 μ l aliquot of the assay solution was loaded into a C-18 column (Polaris C18-A, 50 $\times$ 4.6 mm, 5 μ , 180 Å, Varian; Polaris, Palo Alto, CA, USA) connected

to an automated High-Throughput Liquid Chromatography instrument (Cohesive Technologies, HTLC, Franklin, MA, USA). The radioactive material from the column was detected with a β -RAM model 3 Radio-HPLC detector (IN/US, Tampa, FL, USA). Substrate and product peaks were separated by using an isocratic mixture of 38:62 methanol to water (v/v) at a flow rate of 1.0 ml/min. Under these experimental conditions, the retention time for cortisone and cortisol were 4.5 and 5.5 min respectively. The initial reaction velocities recorded were in the linear range and were determined by measuring the peak area for cortisol formation with time.

Recombinant protein kinetic analysis

The inhibition of 11 β -HSD1 by PF-877423 was analysed by fitting to the equation described below (Equation (1); Morrison 1969) and provided an accurate measurement for the value of K_{iapp} at a fixed concentration of cortisone

$$V_i = V_o \left(1 - \frac{([E]_o + [I]_o + K_{iapp} - \sqrt{([E]_o + [I]_o + K_{iapp})^2 - 4[E]_o[I]_o})}{2[E]_o} \right) \quad (1)$$

where $[E]_o$ and $[I]_o$ are the active enzyme and inhibitor concentration respectively; V_i and V_o are the rates of cortisone reduction in the presence or in the absence of inhibitor respectively. Four K_{iapp} values were determined by varying the cortisone concentration while keeping the concentration of NADPH constant at 500 μ M in the assay buffer. The true inhibition constant, K_i , for PF-877423 was then obtained by plotting the K_{iapp} values versus the cortisone concentration, $[C]_o$, and fitting the data using Equation (2) for a competitive inhibitor

$$K_{iapp} = K_i \left(1 + \frac{[C]_o}{K_m} \right) \quad (2)$$

where K_m was the Michaelis–Menten constant for cortisone.

HEK293 and Chubb-S7 cell culture

HEK293 cells stably transfected with human 11 β -HSD1 (HEK293T1) or 11 β -HSD2 (HEK293T2) cDNA as described previously (Bujalska *et al.* 1997a) were used to study the specificity of inhibitor PF-877423 upon 11 β -HSDs. Cells were cultured in minimum essential medium (MEM) media supplemented with 10% fetal bovine serum (FBS) and 1% non-essential fatty acids; for experiments, cells were seeded into 24-well tissue culture dishes and maintained in MEM with 10% FBS until confluence.

The Chub-S7 cell line was derived from human subcutaneous adipose tissue (Darimont *et al.* 2003) by co-expression of human telomerase reverse transcriptase and papillomavirus E7

oncoprotein (HPV-E7) genes. The cell line has an unlimited life span and the capacity to accumulate lipid without chromosomal alteration. Confluent Chub-S7 cells were cultured in 75 cm² TC flasks in DMEM/Ham's F-12 medium supplemented with 10% FBS. For experiments, cells were seeded in 24-well plates at density 10⁵ cells/well. Chub-S7 were differentiated (up to 21 days) according to Hauner *et al.* (1987) with 166 nM human insulin (I-9278 Sigma), 1 μ M PPAR γ agonist (GW1929, Camlab, Cambridge, UK) and, where specified, with the addition of 1 μ M cortisol (F). For inhibition studies, Chub-S7 cells were differentiated with 0.5 μ M cortisone (E) and an optimised concentration of the selective 11 β -HSD1 inhibitor, PF-877423, at a final concentration of 100 nM.

Human subcutaneous stromal-vascular cell differentiation

Confluent human subcutaneous stromal-vascular (s-v) cells (96-well plates) were obtained from Zen-Bio Inc. (Research Triangle Park, NC, USA) and allowed to recover overnight at 37 °C 5% CO₂. The following day, day 0, differentiation was initiated by incubating cells in differentiating media, DM2(E) (Zen-Bio Inc.), which consists of DMEM/Ham's F-12 medium containing FBS, L-glutamine, penicillin/streptomycin, insulin, indomethacin, 3-isobutyl-1-methylxanthine with 1 μ M E and vehicle (DMSO not exceeding 0.1%). To define the effect of the PF-877423 inhibitor upon the differentiation of primary preadipocytes, cultures were supplemented with 300 nM PF-877423 (in DMSO). Control cells cultured without E. Media were replenished and PF-877423 or vehicle treatment repeated every 2–3 days, except when 11 β -HSD1 activity was assessed.

Measuring lipid content in human subcutaneous s-v cells

Lipogenesis in human subcutaneous s-v cells was measured as triglyceride accumulation. Cells were carefully washed with PBS and lysed *in situ* by adding 50 μ l/well of Hecameg (10% solution in water – Calbiochem, Nottingham, UK). After gentle shaking at room temperature for 10 min, 200 μ l triglyceride (Infinity) reagent (Thermo DMA, Louisville, CO, USA) was added to each well. Plates were read after 10–20 min at 500 nm with correction at 660 nm (Spectra MAX PLUS – Molecular Devices Corporation, Sunnyvale, CA, USA). Results were expressed as optical density (OD) values.

HEK293 and Chubb-S7 11 β -HSD assay

Cells were washed and incubated with 100 nM F (for dehydrogenase activity) or E (for oxo-reductase activity) with appropriate tritiated tracer – ³H F (Du Pont, Stevenage, UK) or ³H E (0.02 μ Ci/reaction; Bujalska *et al.* 1999). PF-877423 specificity upon 11 β -HSD1 was carried out with the addition of 100 nM inhibitor to HEK293T1 and HEK293T2 cells 24 h before and during the enzyme assay. After 3 h incubation with substrate, media was removed and steroids extracted with 4 ml dichloromethane, evaporated under the air and reconstituted

with 70 μ l dichloromethane, then spotted on silica plates (Sigma–Aldrich). Steroids were separated by thin-layer chromatography in chloroform and ethanol (92:8) and steroid conversion was quantified using a LabLogic AR-200 scanner (LabLogic, Sheffield, UK). Cells were washed and protein concentration was measured using colorimetric 96-well plate assay (Bio-Rad) and total RNA was extracted.

Human subcutaneous s-v cells 11 β -HSD1 assay

During 11 β -HSD1 activity assessment in human subcutaneous s-v cells, the medium was changed to basal medium (BM-1, Zen-Bio Inc.) containing only antibiotics, and cells were cultured for 24 h in the presence of PF-877423 with or without 0.5 μ M E. At the end of the incubation, the cortisol signal was quantitatively determined in the 100 μ l cell supernatant with the Correlate-Enzyme Immunoassay Cortisol kit (Assay Designs Inc. Ann Arbor, MI, USA) following the manufacturers' instructions. Plates were read on a plate reader (Spectra MAX PLUS – Molecular Devices Corporation) at 405 nm, with correction at 580 nm. Activity has been expressed as cortisol production in pg/ml per 24 h.

Total RNA extraction and RT reaction

Total RNA was extracted from cells using TriReagent (Sigma) according to the manufacturer's protocol. Integrity and concentration of RNA were assessed by electrophoresis and spectrophotometry respectively. Reverse transcription was carried out using AMV and random primers at 37 °C for 1 h. All RT reagents were purchased from Promega.

PCR

Expression studies were carried out using gene specific primers for human 11 β -HSD1, hexose 6-phosphate dehydrogenase (H6PDH), glucocorticoid receptor α (GR α , FABP4), G3PD, glucose transporter 4 (GLUT-4) and PPAR γ . All primers were designed using primer 3 software (<http://frodo.wi.mit.edu/cgi-bin/primer3/primer3.cgi>) and their sequences from 5' to 3' are shown in Table 1. Primers for 18S as internal control were purchased from Ambion (Quantum RNATM Classic 18S Internal Standard #1716; Ambion). PCRs were carried out at 95 °C for 30 s, 60 °C for 30 s and 72 °C for 30 s in 20 μ l final volume for 30 cycles.

Real-time PCR

Quantitative mRNA expression levels of 11 β -HSD1, H6PDH, GR α , FABP4, G3PD, GLUT-4 and PPAR γ 2 were measured by real-time PCR using an ABI 7500 system (Perkin–Elmer, Biosystems, Warrington, UK). PCR was performed in 25 μ l reactions on 96-well plates. Reactions contained TaqMan universal PCR master mix (Applied Biosystems, Foster City, CA, USA), 900 nmol primers, 100–200 nmol TaqMan probe and 25–50 ng cDNA. All reactions were correlated to expression

Table 1 Primer sequences for various human genes for the PCR

	Forward	Reverse
Gene		
HSD11B1	ACCAGAGATGCTCCAAGGAA	ATGCTTCCATTGCTCTGCTT
H6PDH	AGAAGCGAGACAGCTTCCAC	GCTGCTGGGAAAAGAACAAC
GRα	TCGACCAAGTGTCCAGAGAAC	TTTCGGAACCAACGGGAATTG
GLUT-4	GCCATTGTTATCGGCATTCT	CTACCCCTGCTGTCTCGAAG
PPARγ1	TCTCTCCGTAATGGAAGACC	GCATTATGAGACATCCCCAC
PPARγ2	GCGATTCTTCACTGATAC	GCATTATGAGACATCCCCAC
G3PD	GGAAGACATTGGAGGCAAAA	CCACGGCCACTACATTCTTT
FABP4	CATCAGTGTGAATGGGGATG	ATGCGAACTTCAGTCCAGGT

Primers were designed using Primer3 software (<http://frodo.wi.mit.edu/cgi-bin/primer3>).

of ribosomal 18S rRNA (provided as a pre-optimized mix; Perkin–Elmer) as an internal reference. All target gene probes were labelled with the fluorescent label FAM and the 18S probe with the fluorescent label VIC. Reactions were as follows: 50 °C for 2 min, 95 °C for 10 min, and then 40 cycles of 95 °C for 15 s and 60 °C for 1 min. Data were analysed according to the manufacturer’s guidelines and were obtained as *C_t* values (the cycle number at which logarithmic PCR plots cross a calculated threshold line) and used to determine *dC_t* values (*dC_t* = *C_t* of the target gene minus *C_t* of the internal reference, 18S). Primers and probes for 11β-HSD1, H6PDH and G3PD were designed using PrimerExpress 1.0 software (Applied Biosystems). Sequences from 5′ to 3′ are shown in Table 2. Expression assay kits were purchased from Applied Biosystems to measure the gene expression of GRα, GLUT-4, PPARγ2 and FABP4.

Statistical analysis

Where data were normally distributed, unpaired Student’s *t*-test was used to compare single treatments with control. If normality tests failed, then non-parametric tests were used. One-way ANOVA on ranks was used to compare multiple treatments (SigmaStat 3.1, Systat Software Inc., Point Richmond, CA, USA). Results were expressed as mean values ± S.D. or S.E.M. values and a *P* value of <0.05 was accepted as statistically significant. Statistical analysis on real-time PCR data was performed on mean *ΔC_t* values and not on fold changes.

Results

Kinetics of PF-877423 upon recombinant 11β-HSD1 protein

The potency for PF-877423 was strongly affected by the presence of the substrate in the assay buffer (Fig. 1): *K_i^{app}* values increased at high cortisone concentration, suggesting that the inhibitor behaved as a reversible and competitive inhibitor against cortisone. Fitting the experimental data using equation (2) provided a value of 0.2 ± 0.04 and 333.4 ± 109.2 nM for the inhibition constant, *K_i*, and the apparent Michaelis–Menten constant, *K_m* respectively.

Specificity of PF-877423

11β-HSD enzyme assays on HEK293T1 and HEK293T2 cells showed total abolition of dehydrogenase (12.4 ± 1.0 vs 0.2 ± 0.01, % cortisol to cortisone conversion, mean ± S.D.) and oxo-reductase (34.7 ± 0.6 vs 0.4 ± 0.1, % cortisone to cortisol conversion, mean ± S.D.) activities of 11β-HSD1 following incubation with 100 nM PF-877423 for 24 h (Fig. 2A), but PF-877423 had no effect on 11β-HSD2 activity (63.6 ± 4.0 vs 62.2 ± 4.4, % cortisol to cortisone conversion, mean ± S.D., control versus PF-877423 respectively; Fig. 2B). No toxic effects of PF-877423 were observed up to 10 μM concentrations using a commercially available assay kit (CellTiter 96 Aqueous, Promega; data not shown).

Table 2 Primer and probe sequences for various human genes for the real-time PCR

	Forward	Reverse	Probe
Gene			
HSD11B1	AGGAAAGCTCATGGGAGGACTAG	ATGGTGAATATCATCATGAA AAAGATTC	CATGCTCATTCTCAACCACATCA CCAACA
H6PDH	GGGCCTATGGAACCTCCAA	GACCCACGTTTCTCACTGAC TCT	CCGTGGCGCTACTCATGGACAC A
PPARγ2	AGAAGAAGCGGCGTTGTC	TCAGGTTGAGGCCACCATC	AGGGGCCACACAGACTTGCAC AT
G3PD	CCATCAGTTCATCGGAAGAT	TCGTCTACCCCTTAATAAG AGATATG	AGGGCCATCTGAAGGCAACGC C

Primers and probes were designed using PrimerExpress software (Applied Biosystems, UK).

Figure 1 Effect of cortisone concentration upon the apparent inhibition constant K_{iapp} of the inhibitor PF-877423: a value for the true inhibition constant K_i (0.2 ± 0.04 nM) and the Michaelis–Menten constant K_m (333.4 ± 109.2 nM) is calculated by fitting the experimental data using equation (2).

Characterisation of chub-S7 cells

At confluence (day 0), Chub-S7 cells did not accumulate lipid droplets (Fig. 3A); however, they readily underwent adipogenesis (shown as oil red O staining) when cultured for 21 days in chemically-defined, serum-free media (166 nM insulin, 1 μ M PPAR γ agonist and 1 μ M F; Fig. 3B). As demonstrated by conventional PCR, confluent undifferentiated Chub-S7 cells expressed GR α , H6PDH and PPAR γ 1 mRNA but not

11 β -HSD1, PPAR γ 2, GLUT-4, G3PD or FABP4 mRNA (Fig. 3C). In the differentiated Chub-S7 cells, increased expression of adipogenic markers including G3PD and FABP4 was observed. This process resulted in an increase in 11 β -HSD1, GLUT-4 and PPAR γ 2 mRNA levels (Fig. 3D).

Across differentiation, 11 β -HSD1 oxo-reductase activity increased significantly; from nil on day 0 to 0.4 ± 0.2 on day 3, 5.3 ± 0.7 on day 5, 8.4 ± 0.14 on day 7, 10.5 ± 1.9 on day 9 and 5.9 ± 1.9 on day 16 (pmol/mg per h, mean $\pm$ s.d., $n=7$, all $P<0.01$ versus previous time point; Fig. 4A). Conventional PCR findings were endorsed and quantified by real-time PCR. Expression of 11 β -HSD1 mRNA increased 2.9-fold on day 5, 3.6-fold on day 7, 3.4-fold on day 9 ($P<0.01$) and 38.1-fold on day 16 ($P<0.001$) when compared with day 3, $n=4$ (Fig. 4B).

We observed a transient increase in H6PDH mRNA levels (11 β -HSD1 co-factor provider) – 2.9-fold on day 3, 3.5-fold on day 5, 3.7-fold on day 7, 3.4-fold on day 9 and 0.6-fold on day 16 versus day 0, $P<0.01$ (Fig. 4C) – but there was no significant change in GR α mRNA during Chub-S7 differentiation (Fig. 4D).

Significant increases in differentiation markers FABP4 (2-fold on day 5 ($P<0.01$), 38-fold on day 7, 142-fold on day 9 and 870-fold on day 16 versus day 3, $P<0.001$) and G3PD (4.5-fold on day 7 ($P<0.01$), 22-fold on day 9 and 380-fold on day 16 versus day 5, $P<0.001$) were also observed (Fig. 5A and B respectively). When compared with day 7, the expression of adipocyte-specific genes including GLUT-4 and PPAR γ 2 also increased – 2.1-fold on day 9 and 9.8-fold on day 16, $P<0.01$ (GLUT-4) and 1.3-fold on day 7 and 2.2-fold on day 16, $P<0.01$ (PPAR γ 2; Fig. 5C and D respectively).

Figure 2 (A) PF-877423 inhibits 11 β -HSD1 enzyme activity (dehydrogenase: 12.4 ± 1.0 vs 0.2 ± 0.01 , % cortisol to cortisone conversion, and oxo-reductase: 34.7 ± 0.6 vs 0.4 ± 0.1 , % cortisone to cortisol conversion, mean $\pm$ s.d.) as measured in HEK293T1 (HEK293 cells stably transfected with human 11 β -HSD type 1 cDNA), $n=3$ but not (B) 11 β -HSD2 enzyme activity (63.6 ± 4.0 vs 62.2 ± 4.4 , % cortisol to cortisone conversion, mean $\pm$ s.d., control versus PF-877423 respectively) as measured in HEK293T2 (cells stably transfected with human 11 β -HSD type 2 cDNA), $n=3$. P values: ** $P<0.01$, *** $P<0.001$.

Glucocorticoid metabolism and adipogenesis in Chub-S7 cells incubated with PF-877423

Chub-S7 cells differentiated for 10 days with 500 nM cortisone showed increased 11 β -HSD1 oxo-reductase activity: 14.6 ± 2.3 (E) versus 3.4 ± 1.3 (control), pmol/mg per h mean $\pm$ s.e.m., $P<0.001$ (Fig. 6A), and mRNA expression (14.1-fold versus control; Fig. 6B). Co-incubation with 100 nM PF-877423 abolished this effect: 14.6 ± 2.3 (E) versus 1.3 ± 1.1 (E + PF-877423) vs 0.6 ± 0.5 (PF-877423) pmol/mg per h, mean $\pm$ s.e.m. (Fig. 6A) and 14.1-fold (E) versus 1.2-fold (E + PF-877423), 11 β -HSD1 activity and mRNA respectively (Fig. 6B). Differentiated Chub-S7 cells with E showed increased expression of the adipogenic markers FABP4 (312-fold versus control, $P<0.001$) and G3PD (47-fold versus control, $P<0.001$) – an effect that was completely abolished by co-incubation with PF-877423 (1.3- and 0.7-fold, FABP4 and G3PD respectively; Fig. 6C and D). The change in adipogenesis following incubation with the 11 β -HSD1-specific inhibitor was confirmed visually through staining the cells with oil red O after 21 days of differentiation. A marked increase in the number of red-stained cells was observed in cells differentiated with E or F but not in the presence of PF-877423 (Fig. 6E).

Figure 3 Oil red O staining in (A) confluent Chub-S7 cells (day 0) and (B) differentiated Chub-S7 (day 21). RT-PCR analysis (30 cycles) of nine gene expressions in (C) confluent Chub-S7 cells and (D) in differentiated Chub-S7 cells.

Human subcutaneous s-v cells differentiation

Human subcutaneous s-v cells differentiated with E+PF-877423 had significantly lower 11β-HSD1 oxo-reductase activity compared with cells differentiated with E at any time point studied (day 6: 154±8 vs 5387±182; day 9: 128±1 vs 5489±230; day 14: 174±18 vs 4041±106; day 20: 409±27 vs 10443±78; day 22: 330±7 vs 11218±193 pg/ml per 24 h, mean±s.d., $P<0.001$, $n=3$, E- or E+PF-877423 treated respectively (Fig. 7A)). Lipid content in cells differentiated with E and PF-877423 was significantly lower than in cells

differentiated with E only and similar to undifferentiated cells (day 16, 0.25±0.03 vs 0.20±0.01; day 20, 0.3±0.02 vs 0.20±0.01; day 22, 0.27±0.01 vs 0.19±0.01; OD (500/660 nm); mean±s.d., $P<0.01$, $n=3$, E- or E+PF-877423 treated respectively; Fig. 7B).

Discussion

Numerous studies (Hauner *et al.* 1989, Gregoire *et al.* 1991, Wolf 1999), including our own (Bujalska *et al.* 1999, 2002b), have

Figure 4 (A) 11β-HSD1 oxo-reductase activity (cortisone to cortisol conversion); nil on day 0 to 0.4±0.2 on day 3, 5.3±0.7 on day 5, 8.4±0.14 on day 7, 10.5±1.9 on day 9 and 5.9±1.9 on day 16, pmol/mg per h, mean±s.d. versus previous time point, $n=7$ and mRNA levels measured by real-time PCR of (B) 11β-HSD1 (2.9-fold increase on day 5, 3.6-fold on day 7, 3.4-fold on day 9 and 38.1-fold on day 16 when compared with day 3). (C) H6PDH increased 2.9-fold on day 3, 3.5-fold on day 5, 3.7-fold on day 7, 3.4-fold on day 9 and 0.6-fold on day 16 versus day 0 and (D) GRα (no significant change) across Chub-S7 differentiation, $n=4$. P values: ** $P<0.01$, *** $P<0.001$.

Figure 5 Gene expression analysed by real-time PCR of adipogenic markers; (A) FABP4: (log scale) 2-fold increase on day 5, 38-fold on day 7, 142-fold on day 9 and 870-fold on day 16 versus day 3; (B) G3PD: 4.5-fold on day 7, 22-fold on day 9 and 380-fold on day 16 versus day 5; (C) PPAR γ 2: 1.3-fold on day 9 and 2.2-fold on day 16 versus day 7; and (D) GLUT-4: 2.1-fold on day 9 and 9.8-fold on day 16 versus day 7 across Chub-S7 cell differentiation. *P* values: ***P*<0.01, ****P*<0.001.

defined the permissive role of GCs in inducing adipocyte differentiation. Here, we extend those observations to a novel transformed human adipocyte cell line that should greatly enhance *in vitro* human-based adipocyte research studies. Within 5 days of incubation in chemically defined media comprising insulin, PPAR γ agonist and glucocorticoid, impressive differentiation was observed in Chub-S7 cells as assessed by markers including FABP4, G3PD and adipocyte-specific genes such as GLUT-4 and PPAR γ 2. Adipogenesis was an ongoing process up to 16 days in culture with intracellular lipid stores confirmed by oil red O staining. No significant changes were observed in GR α expression during this differentiation phase; earlier studies had reported increased GR expression in omental versus subcutaneous adipose tissue and had argued that this may be the one factor explaining the predilection of glucocorticoids for visceral obesity (Bronnegard *et al.* 1990). However, more recently our array and real-time PCR analyses failed to demonstrate any difference in GR expression between human omental and subcutaneous preadipocytes (Bujalska *et al.* 2006) and adipose tissue (unpublished data). Together with the data in this study, it seems unlikely that changes in GR expression *per se* are important in the adipogenesis process.

At a pre-receptor level our group has focussed on the role of 11 β -HSD1 and the regeneration of cortisol from inactive cortisone in human adipose tissue. Previously we have demonstrated increased expression of 11 β -HSD1 in omental compared with subcutaneous depots (Bujalska *et al.* 1997b), and importantly a switch in the directionality of enzyme activity from predominant dehydrogenase to oxo-reductase (Bujalska *et al.* 2002a), probably as a result of induction of the NADPH donor source for 11 β -HSD1 within the endoplasmic reticulum (ER) lumen, H6PDH (Ozols 1993). In support of these

observations, in this study, the rise in H6PDH mRNA levels probably explained the increase in 11 β -HSD1-mediated oxo-reductase activity between days 3 and 9 in addition to an increase in 11 β -HSD1 mRNA levels. Furthermore, decreased H6PDH mRNA expression seen on day 16 might account for the decline in 11 β -HSD1 oxo-reductase activity despite high mRNA. The impressive increase in 11 β -HSD1 expression across adipocyte differentiation has been noted recently in mouse 3T3-L1 cells (Kim *et al.* 2007), as it has been done in other differentiating cell systems including osteoblasts (Eijken *et al.* 2005). In both cases cells have been incubated with glucocorticoids that themselves positively regulate 11 β -HSD1 (Bujalska *et al.* 1997b); it is not possible from these or previous data sets to conclude whether or not the increased 11 β -HSD1 expression is glucocorticoid mediated or a manifestation of the differentiation process *per se*.

Nevertheless, 11 β -HSD1 expression, resulting in a functionally active oxo-reductase, was clearly linked to the differentiation phenotype. Incubation of Chub-S7 cells with inactive steroid, cortisone, induced a degree of adipocyte differentiation similar to that observed with cortisol. This could be explained on the basis of 11 β -HSD1-mediated oxo-reductase activity with a K_m for cortisone in Chubb-S7 cells of 100 nM which is similar to the reports in other 11 β -HSD1-expressing cell systems (Monder & Lakshmi 1989, Ricketts *et al.* 1998) including studies on the recombinant enzyme (K_m = 333 nM; Walker *et al.* 2001, Shafqat *et al.* 2003). Evaluation of the competitive 11 β -HSD1 inhibitor, PF-877423, indicated selectivity for the type 1 11 β -HSD isoform with a K_i = 0.2 nM in the recombinant assay and IC₅₀ ~ 5 nM in Chubb-S7 cells. Selectivity of the inhibitor towards 11 β -HSD1 isoform but not 11 β -HSD2 is crucial as patients with impairment in the latter are presented with severe hypertension, (White *et al.* 1997).

Figure 6 Chub-S7 cells differentiated with 0.5 μ M E and with or without the selective 11 β -HSD1 inhibitor PF-877423 at 100 nM. All experiments were carried out on differentiated cells on day 10, $n=3$. (A) 11 β -HSD1 oxo-reductase activity (cortisone to cortisol conversion): 14.6 ± 2.4 (E) versus 1.2 ± 1.1 (E+PF-877423) vs 3.4 ± 1.3 (control), pmol/mg per h mean $\pm$ S.E.M., $P<0.001$, (B) 11 β -HSD1 mRNA expression and adipogenic markers (C) FABP4, (D) G3PD (log scale, $P<0.001$ and $P<0.001$ respectively) and (E) Chub-S7 cells differentiated for 21 days and stained with oil red O; 1) control: 166 nM insulin, PPAR γ agonist, 100 nM PF-877423, 2) 0.5 μ M E, 3) 0.5 μ M E+100 nM PF-877423 and 4) positive control (differentiation with 0.5 μ M F). P values: ** $P<0.01$, *** $P<0.001$.

PF-877423 selectivity was undertaken using a transformed cell line expressing human 11 β -HSD2 enzyme where no inhibitory effect was observed. Incubation of cells with 100 nM PF-877423 completely abolished the cortisone induction of FABP4, G3PDH and 11 β -HSD1 itself in Chubb-S7 cells. We also demonstrated that the transformed cell line data were consistent with data in primary human subcutaneous preadipocytes. While incubation with cortisone yielded a less impressive effect on adipogenesis in human subcutaneous preadipocytes when compared with Chubb-S7 cells (this might reflect a more advanced adipogenic lineage of primary cultures), inhibition of 11 β -HSD1 activity nevertheless reduced the ability of human subcutaneous preadipocytes to differentiate and accumulate lipid.

Whilst the cell line that we have used is subcutaneous in origin and the expression of 11 β -HSD1 is higher in omental human preadipocytes (Bujalska *et al.* 1997b) and therefore we predict that the impact upon omental cells would be more

pronounced. We anticipate that this would not lead to preferential loss of subcutaneous fat. Unfortunately, omental cell lines are not available for study and *in vivo* human clinical studies have not been performed.

Previously, non-selective 11 β -HSD inhibitors have been shown to diminish human adipocyte differentiation *in vitro* (Bujalska *et al.* 1999) and increase insulin sensitivity in man (Walker *et al.* 1995), but a lack of isozyme selectivity can cause water retention and hypertension. Since then, patents have been filed on compounds that report to be selective 11 β -HSD1 inhibitors. An aryl sulphonamide derivative has been shown to reduce insulin levels and improve glucose tolerance when administered to rodents for 7 days (Alberts *et al.* 2002). Similar data have been reported for an adamantyl triazole that also reduced body weight and the progression of atherosclerosis in mice (Hermanowski-Vosatka *et al.* 2005). Transgenic mouse models have established 11 β -HSD1 as a novel therapeutic target in this regard; global deletion of 11 β -HSD1 results in improved

Figure 7 (A) Effect of chronic exposure to the selective 11 β -HSD1 inhibitor PF-877423 on subcutaneous s-v cells. 11 β -HSD1 enzyme inhibition by 300 nM PF-877423 measured as the production of cortisol (day 6: 154 ± 8 vs 5387 ± 182; day 9: 128 ± 1 vs 5489 ± 230; day 14: 174 ± 18 vs 4041 ± 106; day 20: 409 ± 27 vs 10443 ± 78; day 22: 330 ± 7 vs 11218 ± 193 pg/ml per 24 h, mean ± s.d., $P < 0.001$, $n = 3$, E- or E+PF-877423-treated respectively). (B) Inhibition of lipid accumulation by 300 nM PF-877423 in subcutaneous stromal-vascular cells (day 16: 0.25 ± 0.03 vs 0.20 ± 0.01; day 20: 0.3 ± 0.02 vs 0.20 ± 0.01; day 22: 0.27 ± 0.01 vs 0.19 ± 0.01; OD (500/660 nm), $n = 3$, E- or E+PF-877423-treated respectively), P values: ** $P < 0.01$, *** $P < 0.001$.

glucose tolerance through reduced gluconeogenesis and hepatic glucose output (Kotelevtsev *et al.* 1997, Morton *et al.* 2001), while targeted overexpression of 11 β -HSD1 in adipose tissue recapitulates features of the MS including central adiposity (Masuzaki *et al.* 2001). In the liver of db/db mice (a model of type 2 diabetes), GR and 11 β -HSD1 mRNA expression positively correlated with blood insulin and glucose (Liu *et al.* 2005). Inhibition of GR and 11 β -HSD1 expression either with GR antagonist (RU486; Liu *et al.* 2005) or by chronic activation of liver X receptor (Liu *et al.* 2006) attenuated the phenotype of type 2 diabetes in mice.

In humans, the situation is less clear with regard to a role for 11 β -HSD1 in the pathogenesis of MS. Some authors have argued for a primary overexpression of 11 β -HSD1 in affected patients akin to that observed in some animal models (Paulmyer-Lacroix *et al.* 2002, Rask *et al.* 2002). However, while the expression of 11 β -HSD1 might be increased, at least in subcutaneous adipose tissue in obese patients with MS and type 2 diabetes (Tomlinson *et al.* 2002, Alberti *et al.* 2007), no such increase was observed in omental adipose tissue. Furthermore, based on urinary cortisol/cortisone metabolite ratios and plasma cortisol generation curves following oral cortisone acetate that primarily reflects hepatic 11 β -HSD1 expression, a reduction, not an increase, in 11 β -HSD1 expression was observed at least in subjects with simple obesity (Stewart *et al.* 1999, Tomlinson *et al.* 2004). We have argued that obesity is not primarily a state of 11 β -HSD1 overexpression, but that the fall in hepatic 11 β -HSD1 activity with increased visceral adiposity might serve as a protective mechanism to offset hepatic glucose output and further adiposity (Valsamakis *et al.* 2004). Failure of such a switch off in 11 β -HSD1 expression might be a factor that determines the onset and persistence of hyperglycaemia in obese patients with type 2 diabetes mellitus (Valsamakis *et al.* 2004). Further studies are indicated to define

the exact role of 11 β -HSD1 in the pathophysiology of human MS. Irrespective of the outcome of these studies, selective inhibitors such as PF-877423 offer a real advance in the prevention and treatment of diabetes in subjects with obesity with the potential added benefit of inhibiting adipocyte differentiation. A reduction in adipogenesis specifically within omental depots is likely to further improve the metabolic phenotype of these patients. Clinical studies characterising a novel, potent (K_i 0.2 nM) and fully selective 11 β -HSD1 inhibitor preventing lipogenesis *in vitro* will further our understanding of the role of local glucocorticoid metabolism in human adipose tissue.

Acknowledgements

The work was supported by a Wellcome Trust Programme Grant (Ref No 066357) and MRC Grant (G0502165). The authors thank Jeff Zhu for providing the human 11 β -HSD1 recombinant protein.

Disclosure

I J B, L L G, J W T and C D declare no conflict of interest. J E, A N F and P A R are employed by Pfizer. P M S is on the advisory board for Pfizer Global R&D.

References

- Alberti L, Girola A, Gilardini L, Conti A, Cattaldo S, Micheletto G & Invitti C 2007 Type 2 diabetes and metabolic syndrome are associated with increased expression of 11 β -hydroxysteroid dehydrogenase 1 in obese subjects. *International Journal of Obesity* **31** 1826–1831.

- Alberts P, Engblom L, Edling N, Forsgren M, Klingstrom G, Larsson C, Ronquist-Nii Y, Ohman B & Abrahamson L 2002 Selective inhibition of 11 β -hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. *Diabetologia* **45** 1528–1532.
- Bronnegard M, Arner P, Hellstrom L, Akner G & Gustafsson JA 1990 Glucocorticoid receptor messenger ribonucleic acid in different regions of human adipose tissue. *Endocrinology* **127** 1689–1696.
- Bujalska I, Shimojo M, Howie A & Stewart PM 1997a Human 11 β -hydroxysteroid dehydrogenase: studies on the stably transfected isoforms and localization of the type 2 isozyme within renal tissue. *Steroids* **62** 77–82.
- Bujalska IJ, Kumar S & Stewart PM 1997b Does central obesity reflect 'Cushing's disease of the omentum'? *Lancet* **349** 1210–1213.
- Bujalska IJ, Kumar S, Hewison M & Stewart PM 1999 Differentiation of adipose stromal cells: the roles of glucocorticoids and 11 β -hydroxysteroid dehydrogenase. *Endocrinology* **140** 3188–3196.
- Bujalska IJ, Walker EA, Hewison M & Stewart PM 2002a A switch in dehydrogenase to reductase activity of 11 β -hydroxysteroid dehydrogenase type 1 upon differentiation of human omental adipose stromal cells. *Journal of Clinical Endocrinology and Metabolism* **87** 1205–1210.
- Bujalska IJ, Walker EA, Tomlinson JW, Hewison M & Stewart PM 2002b 11 β -hydroxysteroid dehydrogenase type 1 in differentiating omental human preadipocytes: from de-activation to generation of cortisol. *Endocrine Research* **28** 449–461.
- Bujalska IJ, Quinkler M, Tomlinson JW, Montague CT, Smith DM & Stewart PM 2006 Expression profiling of 11 β -hydroxysteroid dehydrogenase type-1 and glucocorticoid-target genes in subcutaneous and omental human preadipocytes. *Journal of Molecular Endocrinology* **37** 327–340.
- Darimont C, Zbinden I, Avanti O, Leone-Vautravers P, Giusti V, Burckhardt P, Pfeifer AM & Mace K 2003 Reconstitution of telomerase activity combined with HPV-E7 expression allow human preadipocytes to preserve their differentiation capacity after immortalization. *Cell Death and Differentiation* **10** 1025–1031.
- De PR, Green A, Kao MY & Olefsky JM 1981 Effects of prednisolone and dexamethasone *in vivo* and *in vitro*: studies of insulin binding, deoxyglucose uptake and glucose oxidation in rat adipocytes. *Diabetologia* **21** 149–153.
- Eijken M, Hewison M, Cooper MS, de Jong FH, Chiba H, Stewart PM, Uitterlinden AG, Pols HA & van Leeuwen JP 2005 11 β -Hydroxysteroid dehydrogenase expression and glucocorticoid synthesis are directed by a molecular switch during osteoblast differentiation. *Molecular Endocrinology* **19** 621–631.
- Fraser R, Ingram MC, Anderson NH, Morrison C, Davies E & Connell JM 1999 Cortisol effects on body mass, blood pressure, and cholesterol in the general population. *Hypertension* **33** 1364–1368.
- Gregoire F, Genart C, Hauser N & Remacle C 1991 Glucocorticoids induce a drastic inhibition of proliferation and stimulate differentiation of adult rat fat cell precursors. *Experimental Cell Research* **196** 270–278.
- Hauner H, Schmid P & Pfeiffer EF 1987 Glucocorticoids and insulin promote the differentiation of human adipocyte precursor cells into fat cells. *Journal of Clinical Endocrinology and Metabolism* **64** 832–835.
- Hauner H, Entenmann G, Wabitsch M, Gaillard D, Ailhaud G, Negrel R & Pfeiffer EF 1989 Promoting effect of glucocorticoids on the differentiation of human adipocyte precursor cells cultured in a chemically defined medium. *Journal of Clinical Investigation* **84** 1663–1670.
- Hermanowski-Vosatka A, Balkovec JM, Cheng K, Chen HY, Hernandez M, Koo GC, Le Grand CB, Li Z, Metzger JM, Mundt SS *et al.* 2005 11 β -HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. *Journal of Experimental Medicine* **202** 517–527.
- Hotamisligil GS, Johnson RS, Distel RJ, Ellis R, Papaioannou VE & Spiegelman BM 1996 Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. *Science* **274** 1377–1379.
- Kershaw EE, Morton NM, Dhillon H, Ramage L, Seckl JR & Flier JS 2005 Adipocyte-specific glucocorticoid inactivation protects against diet-induced obesity. *Diabetes* **54** 1023–1031.
- Kim J, Temple KA, Jones SA, Meredith KN, Basko JL & Brady MJ 2007 Differential modulation of 3T3-L1 adipogenesis mediated by 11 β -hydroxysteroid dehydrogenase-1 levels. *Journal of Biological Chemistry* **282** 11038–11046.
- Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmolle D, Jamieson P, Best R, Brown R, Edwards CR, Seckl JR *et al.* 1997 11 β -Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. *PNAS* **94** 14924–14929.
- Liu Y, Nakagawa Y, Wang Y, Sakurai R, Tripathi PV, Lutfy K & Friedman TC 2005 Increased glucocorticoid receptor and 11 β -hydroxysteroid dehydrogenase type 1 expression in hepatocytes may contribute to the phenotype of type 2 diabetes in db/db mice. *Diabetes* **54** 32–40.
- Liu Y, Yan C, Wang Y, Nakagawa Y, Nerio N, Anghel A, Lutfy K & Friedman TC 2006 Liver X receptor agonist T0901317 inhibition of glucocorticoid receptor expression in hepatocytes may contribute to the amelioration of diabetic syndrome in db/db mice. *Endocrinology* **147** 5061–5068.
- Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR & Flier JS 2001 A transgenic model of visceral obesity and the metabolic syndrome. *Science* **294** 2166–2170.
- Masuzaki H, Yamamoto H, Kenyon CJ, Elmquist JK, Morton NM, Paterson JM, Shinyama H, Sharp MG, Fleming S, Mullins JJ *et al.* 2003 Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. *Journal of Clinical Investigation* **112** 83–90.
- Monder C & Lakshmi V 1989 Evidence for kinetically distinct forms of corticosteroid 11 β -dehydrogenase in rat liver microsomes. *Journal of Steroid Biochemistry* **32** 77–83.
- Morrison JF 1969 Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors. *Biochimica et Biophysica Acta* **185** 269–286.
- Morton NM, Holmes MC, Fievet C, Staels B, Tailleux A, Mullins JJ & Seckl JR 2001 Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11 β -hydroxysteroid dehydrogenase type 1 null mice. *Journal of Biological Chemistry* **276** 41293–41300.
- Morton NM, Paterson JM, Masuzaki H, Holmes MC, Staels B, Fievet C, Walker BR, Flier JS, Mullins JJ & Seckl JR 2004 Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 β -hydroxysteroid dehydrogenase type 1-deficient mice. *Diabetes* **53** 931–938.
- Olefsky JM 1975 Effect of dexamethasone on insulin binding, glucose transport, and glucose oxidation of isolated rat adipocytes. *Journal of Clinical Investigation* **56** 1499–1508.
- Ozols J 1993 Isolation and the complete amino acid sequence of luminal endoplasmic reticulum glucose-6-phosphate dehydrogenase. *PNAS* **90** 5302–5306.
- Paterson JM, Morton NM, Fievet C, Kenyon CJ, Holmes MC, Staels B, Seckl JR & Mullins JJ 2004 Metabolic syndrome without obesity: hepatic over-expression of 11 β -hydroxysteroid dehydrogenase type 1 in transgenic mice. *PNAS* **101** 7088–7093.
- Paulmyer-Lacroix O, Boullu S, Oliver C, Alessi MC & Grino M 2002 Expression of the mRNA coding for 11 β -hydroxysteroid dehydrogenase type 1 in adipose tissue from obese patients: an *in situ* hybridization study. *Journal of Clinical Endocrinology and Metabolism* **87** 2701–2705.
- Qiao L, Maclean PS, Schaack J, Orlicky DJ, Darimont C, Pagliassotti M, Friedman JE & Shao J 2005 C/EBP α regulates human adiponectin gene transcription through an intronic enhancer. *Diabetes* **54** 1744–1754.
- Rask E, Walker BR, Soderberg S, Livingstone DE, Eliasson M, Johnson O, Andrew R & Olsson T 2002 Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11 β -hydroxysteroid dehydrogenase type 1 activity. *Journal of Clinical Endocrinology and Metabolism* **87** 3330–3336.
- Richon VM, Lyle RE & McGehee RE, Jr 1997 Regulation and expression of retinoblastoma proteins p107 and p130 during 3T3-L1 adipocyte differentiation. *Journal of Biological Chemistry* **272** 10117–10124.
- Ricketts ML, Shoesmith KJ, Hewison M, Strain A, Eggo MC & Stewart PM 1998 Regulation of 11 β -hydroxysteroid dehydrogenase type 1 in primary cultures of rat and human hepatocytes. *Journal of Endocrinology* **156** 159–168.
- Rosen ED & MacDougald OA 2006 Adipocyte differentiation from the inside out. *Nature Reviews. Molecular Cell Biology* **7** 885–896.

- Shafqat N, Elleby B, Svensson S, Shafqat J, Jornvall H, Abrahmsen L & Oppermann U 2003 Comparative enzymology of 11 β -hydroxysteroid dehydrogenase type 1 from glucocorticoid resistant (guinea pig) versus sensitive (human) species. *Journal of Biological Chemistry* **278** 2030–2035.
- Slavin BG, Ong JM & Kern PA 1994 Hormonal regulation of hormone-sensitive lipase activity and mRNA levels in isolated rat adipocytes. *Journal of Lipid Research* **35** 1535–1541.
- Stewart PM, Boulton A, Kumar S, Clark PM & Shackleton CH 1999 Cortisol metabolism in human obesity: impaired cortisone $\rightarrow$ cortisol conversion in subjects with central adiposity. *Journal of Clinical Endocrinology and Metabolism* **84** 1022–1027.
- Tomlinson JW, Sinha B, Bujalska I, Hewison M & Stewart PM 2002 Expression of 11 β -hydroxysteroid dehydrogenase type 1 in adipose tissue is not increased in human obesity. *Journal of Clinical Endocrinology and Metabolism* **87** 5630–5635.
- Tomlinson JW, Moore JS, Clark PM, Holder G, Shakespeare L & Stewart PM 2004 Weight loss increases 11 β -hydroxysteroid dehydrogenase type 1 expression in human adipose tissue. *Journal of Clinical Endocrinology and Metabolism* **89** 2711–2716.
- Valsamakis G, Anwar A, Tomlinson JW, Shackleton CH, McTernan PG, Chetty R, Wood PJ, Banerjee AK, Holder G, Barnett AH *et al.* 2004 11 β -hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus. *Journal of Clinical Endocrinology and Metabolism* **89** 4755–4761.
- Walker BR, Connacher AA, Lindsay RM, Webb DJ & Edwards CR 1995 Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation. *Journal of Clinical Endocrinology and Metabolism* **80** 3155–3159.
- Walker EA, Clark AM, Hewison M, Ride JP & Stewart PM 2001 Functional expression, characterization, and purification of the catalytic domain of human 11 β -hydroxysteroid dehydrogenase type 1. *Journal of Biological Chemistry* **276** 21343–21350.
- White PC, Mune T & Agarwal AK 1997 11 β -Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. *Endocrine Reviews* **18** 135–156.
- Wolf G 1999 The molecular mechanism of the stimulation of adipocyte differentiation by a glucocorticoid. *Nutrition Reviews* **57** 324–326.
- Wu Z, Bucher NL & Farmer SR 1996 Induction of peroxisome proliferator-activated receptor gamma during the conversion of 3T3 fibroblasts into adipocytes is mediated by C/EBP β , C/EBP δ , and glucocorticoids. *Molecular and Cellular Biology* **16** 4128–4136.
- Yang S, Xu X & Bjorntorp P 1993 Effects of dexamethasone on primarily cultured newly differentiated rat adipocytes from different adipose tissue regions. *Obesity Research* **1** 99–105.

Received in final form 26 February 2008

Accepted 4 March 2008

Made available online as an Accepted Preprint
4 March 2008